CoChat

New targets for rapid antidepressant action

Open access
Machado-Vieira, Rodrigo, Henter, Ioline D., Zarate Jr., Carlos A. · 2017 · Progress in Neurobiology
Cited by 154

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

Current therapeutic options for major depressive disorder (MDD) and bipolar disorder (BD) are associated with a lag of onset that can prolong distress and impairment for patients, and their antidepressant efficacy is often limited. All currently approved antidepressant medications for MDD act primarily through monoaminergic mechanisms. Glutamate is the major excitatory neurotransmitter in the central nervous system, and glutamate and its cognate receptors are implicated in the pathophysiology of MDD, and in the development of novel therapeutics for this disorder. The rapid and robust antidepressant effects of the N-methyl-D-aspartate (NMDA) antagonist ketamine were first observed in 2000. Since then, other NMDA receptor antagonists have been studied in MDD. Most have demonstrated relatively modest antidepressant effects compared to ketamine, but some have shown more favorable characteristics. This article reviews the clinical evidence supporting the use of novel glutamate receptor modulators with direct affinity for cognate receptors: 1) non-competitive NMDA receptor antagonists (ketamine, memantine, dextromethorphan, AZD6765); 2) subunit (GluN2B)-specific NMDA receptor antagonists (CP-101,606/traxoprodil, MK-0657); 3) NMDA receptor glycine-site partial agonists (GLYX-13); and 4) metabotropic glutamate receptor (mGluR) modulators (AZD2066, RO4917523/basimglurant). We also briefly discuss several other theoretical glutamate receptor targets with preclinical antidepressant-like efficacy that have yet to be studied clinically; these include α-amino-3-hydroxyl-5-methyl-4-isoxazoleproprionic acid (AMPA) agonists and mGluR2/3 negative allosteric modulators. The review also discusses other promising, non-glutamatergic targets for potential rapid antidepressant effects, including the cholinergic system (scopolamine), the opioid system (ALKS-5461), corticotropin releasing factor (CRF) receptor antagonists (CP-316,311), and others.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2015.12.001

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Research works printed but not linked: 146

  1. Abdallah, 2015, Ketamine as a promising prototype for a new generation of rapid-acting antidepressants, Ann. N.Y. Acad. Sci., 1344, 66, 10.1111/nyas.12718 · DOI · Paper page
  2. Ahn, 2008, Chronotype distribution in bipolar I disorder and schizophrenia in a Korean sample, Bipolar Disord., 10, 271, 10.1111/j.1399-5618.2007.00573.x · DOI
  3. Alaerts, 2006, Lack of association of an insertion/deletion polymorphism in the G protein-coupled receptor 50 with bipolar disorder in a Northern Swedish population, Psychiatr. Genet., 16, 235, 10.1097/01.ypg.0000242193.28526.b3 · DOI
  4. Armstrong, 1993, Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS), Pharmacol. Biochem. Behav., 46, 45, 10.1016/0091-3057(93)90315-K · DOI
  5. Ball, 2014, Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder, Hum. Psychopharmacol., 29, 568, 10.1002/hup.2444 · DOI
  6. Bersani, 2000, Melatonin add-on in manic patients with treatment resistant insomnia, Biol. Psychiatry, 24, 185
  7. Bertaina-Anglade, 2006, Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model, Behav. Pharmacol., 17, 703, 10.1097/FBP.0b013e3280116e5c · DOI
  8. Beurel, 2011, Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice, Mol. Psychiatry, 16, 1068, 10.1038/mp.2011.47 · DOI · Paper page
  9. Bleakman, 2007, AMPA receptors in the therapeutic management of depression, CNS Neurol. Disord. Drug Targets, 6, 117, 10.2174/187152707780363258 · DOI
  10. Bourin, 2009, Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression, Curr. Pharm. Des., 15, 1675, 10.2174/138161209788168056 · DOI
  11. Boyer, 1998, Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study, J. Mol. Neurosci., 10, 219, 10.1007/BF02761776 · DOI
  12. Bredt, 2015, Translating depression biomarkers for improved targeted therapies, Neurosci. Biobehav. Rev., 59, 1, 10.1016/j.neubiorev.2015.09.013 · DOI
  13. Calabrese, 2007, Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data, Bipolar Disord., 9, 628, 10.1111/j.1399-5618.2007.00507.x · DOI · Paper page
  14. Cao, 2010, Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock, J. Neurosci., 30, 6302, 10.1523/JNEUROSCI.5482-09.2010 · DOI
  15. Cardinali, 2011, Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications, Neuroendocrinology, 93, 133, 10.1159/000324699 · DOI
  16. Carlson, 2013, Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study, Biol. Psychiatry, 73, 1213, 10.1016/j.biopsych.2013.02.008 · DOI · Paper page
  17. Castren, 2010, The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity, Dev. Neurobiol., 70, 289, 10.1002/dneu.20758 · DOI · Paper page
  18. Chaki, 2013, mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants, Neuropharmacology, 66, 40, 10.1016/j.neuropharm.2012.05.022 · DOI
  19. Chilukuri, 2014, Acute antidepressant effects of intramuscular versus intravenous ketamine, Indian J. Psychol. Med., 36, 71, 10.4103/0253-7176.127258 · DOI · Paper page
  20. Chung, 1992, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, Cell, 69, 1227, 10.1016/0092-8674(92)90643-Q · DOI · Paper page
  21. Covington, 2010, From synapse to nucleus: novel targets for treating depression, Neuropharmacology, 58, 683, 10.1016/j.neuropharm.2009.12.004 · DOI · Paper page
  22. Dale, 2015, Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs, Biochem. Pharmacol., 95, 81, 10.1016/j.bcp.2015.03.011 · DOI · Paper page
  23. Dawson, 2014, Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks, Neuropsychopharmacology, 39, 1786, 10.1038/npp.2014.26 · DOI
  24. Day, 2012, Epigenetic treatments for cognitive impairments, Neuropsychopharmacology, 37, 247, 10.1038/npp.2011.85 · DOI
  25. DeLorenzo, 2015, Invivo ketamine-induced changes in [C]ABP688 binding to metabotropic glutamate receptor subtype 5, Biol. Psychiatry, 77, 266, 10.1016/j.biopsych.2014.06.024 · DOI
  26. Denk, 2011, Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation, Am. J. Psychiatry, 68, 751, 10.1176/appi.ajp.2011.11010128 · DOI
  27. Drevets, 2013, Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review, Biol. Psychiatry, 73, 1156, 10.1016/j.biopsych.2012.09.031 · DOI · Paper page
  28. Duman, 2015, Spine synapse remodeling in the pathophysiology and treatment of depression, Neurosci. Lett., 601, 20, 10.1016/j.neulet.2015.01.022 · DOI · Paper page
  29. Duman, 2009, Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression, Dialogues Clin. Neurosci., 11, 239, 10.31887/DCNS.2009.11.3/rsduman · DOI · Paper page
  30. Dutta, 2015, Ketamine and other potential glutamate antidepressants, Psychiatry Res., 225, 1, 10.1016/j.psychres.2014.10.028 · DOI
  31. Dwyer, 2013, Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants, Biol. Psychiatry, 73, 1189, 10.1016/j.biopsych.2012.11.011 · DOI
  32. Emnett, 2013, Indistinguishable synaptic pharmacodynamics of the N-methyl-d-aspartate receptor channel blockers memantine and ketamine, Mol. Pharmacol., 84, 935, 10.1124/mol.113.089334 · DOI
  33. Espino, 2011, Role of melatonin on diabetes-related metabolic disorders, World J. Diabetes, 2, 82, 10.4239/wjd.v2.i6.82 · DOI
  34. Garcia, 2008, Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 140, 10.1016/j.pnpbp.2007.07.027 · DOI · Paper page
  35. Geoffrey, 2015, Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders, Curr. Pharm. Des., 21, 3352, 10.2174/1381612821666150619093448 · DOI
  36. Gruber, 2009, Sleep functioning in relation to mood, function, and quality of life at entry to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), J. Affect Disord., 114, 41, 10.1016/j.jad.2008.06.028 · DOI
  37. Hallam, 2006, The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins, Psychoneuroendocrinology, 31, 867, 10.1016/j.psyneuen.2006.04.004 · DOI · Paper page
  38. Hallam, 2005, Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers, Int. J. Neuropsychopharmacol., 8, 255, 10.1017/S1461145704004894 · DOI
  39. Hallam, 2005, Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers, Neuropsychopharmacology, 30, 1400, 10.1038/sj.npp.1300739 · DOI
  40. Hallam, 2005, Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder, Aust. N.Z. J. Psychiatry, 39, 947, 10.1080/j.1440-1614.2005.01705_1.x · doi:10.1080/j.1440-1614.2005.01705_1.x
  41. Hashimoto, 2007, Increased levels of glutamate in brains from patients with mood disorders, Biol. Psychiatry, 62, 1310, 10.1016/j.biopsych.2007.03.017 · DOI · Paper page
  42. Heitman, 1991, Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast, Science, 253, 905, 10.1126/science.1715094 · DOI · Paper page
  43. Hirota, 1996, Ketamine: its mechanism(s) of action and unusual clinical uses, Br. J. Anaesth., 77, 441, 10.1093/bja/77.4.441 · DOI · Paper page
  44. Hirota, 1999, Stereoselective interaction of ketamine with recombinant μ, κ and δ opiod receptors expressed in chinese hamster ovary cells, Anesthesiology, 90, 174, 10.1097/00000542-199901000-00023 · DOI · Paper page
  45. Hoeffer, 2010, mTOR signaling: at the crossroads of plasticity, memory and disease, Trends Neurosci., 33, 67, 10.1016/j.tins.2009.11.003 · DOI · Paper page
  46. Jaffe, 2013, Scopolamine as an antidepressant: a systematic review, Clin. Neuropharmacol., 36, 24, 10.1097/WNF.0b013e318278b703 · DOI
  47. Karasawa, 2005, AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist, Brain Res., 1042, 92, 10.1016/j.brainres.2005.02.032 · DOI
  48. Kennedy, 2006, Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, Eur. Neuropsychopharmacol., 16, 93, 10.1016/j.euroneuro.2005.09.002 · DOI · Paper page
  49. Kennedy, 1996, Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder, Psychiatry Res., 63, 219, 10.1016/0165-1781(96)02910-1 · DOI
  50. Khajavi, 2012, Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study, J. Clin. Psychiatry, 73, 1428, 10.4088/JCP.12m07706 · DOI
  51. Klimek, 1994, The effect of MK-801 and imipramine on beta-adrenergic and 5-HT2 receptors in the chronic mild stress model of depression in rats, Pol. J. Pharmacol., 46, 67
  52. Knoll, 2010, Dynorphin, stress, and depression, Brain Res., 1314, 56, 10.1016/j.brainres.2009.09.074 · DOI · Paper page
  53. Kocsis, 2013, Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits, CNS Neurosci. Ther., 19, 437, 10.1111/cns.12081 · DOI
  54. Koshikawa, 1989, Rapid development of brain beta-adrenoceptor down-regulation induced by phenelzine: subcellular studies, Eur. J. Pharmacol., 170, 101, 10.1016/0014-2999(89)90141-6 · doi:10.1016/0014-2999(89)90141-6
  55. Kotermanski, 2009, Memantine binding to a superficial site on NMDA receptors contributes to partial trapping, J. Physiol., 587, 4589, 10.1113/jphysiol.2009.176297 · DOI
  56. Kramer, 1998, Distinct mechanism for antidepressant activity by blockade of central substance P receptors, Science, 281, 1640, 10.1126/science.281.5383.1640 · DOI · Paper page
  57. Kramer, 2004, Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression, Neuropsychopharmacology, 29, 385, 10.1038/sj.npp.1300260 · DOI · Paper page
  58. Lauterbach, 2011, Dextromethorphan as a potential rapid-acting antidepressant, Med. Hypotheses, 76, 717, 10.1016/j.mehy.2011.02.003 · DOI
  59. Layer, 1995, Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715), Pharmacol. Biochem. Behav., 52, 621, 10.1016/0091-3057(95)00155-P · DOI
  60. Legutko, 2001, Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator, Neuropharmacology, 40, 1019, 10.1016/S0028-3908(01)00006-5 · DOI
  61. Leibenluft, 1997, Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder, J. Clin. Psychiatry, 58, 383, 10.4088/JCP.v58n0902 · DOI
  62. Lewy, 1985, Supersensitivity to light: possible trait marker for manic-depressive illness, Am. J. Psychiatry, 142, 725, 10.1176/ajp.142.6.725 · DOI · Paper page
  63. Lewy, 1981, Manic-depressive patients may be supersensitive to light, Lancet, 1, 383, 10.1016/S0140-6736(81)91697-4 · DOI · Paper page
  64. Li, 2011, Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure, Biol. Psychiatry, 69, 754, 10.1016/j.biopsych.2010.12.015 · DOI · Paper page
  65. Linden, 2000, Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotropic agents, J. Mol. Neurosci., 14, 27, 10.1385/JMN:14:1-2:027 · DOI
  66. Liu, 2004, Muscarinic receptors modulate the mRNA expression of NMDA receptors in brainstem and the release of glutamate in periaqueductal grey during morphine withdrawal in rats, Sheng Li Xue Bao, 56, 95
  67. Livingstone, 2010, Mechanisms governing the control of mRNA translation, Phys. Biol., 7, 021001, 10.1088/1478-3975/7/2/021001 · DOI
  68. Loo, 2002, Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study, Int. Clin. Psychopharmacol., 17, 239, 10.1097/00004850-200209000-00004 · DOI · Paper page
  69. Lozano, 2008, Effects of subcallosal cingulate deep brain stimulation on negative self-bias in patients with treatment-resistant depression, Biol. Psychiatry, 64, 461, 10.1016/j.biopsych.2008.05.034 · DOI · Paper page
  70. Machado-Vieira, 2011, Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions, CNS Neurosci. Ther., 17, 699, 10.1111/j.1755-5949.2010.00203.x · DOI
  71. Machado-Vieira, 2009, Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders, Curr. Pharm. Des., 15, 1595, 10.2174/138161209788168010 · DOI
  72. Machado-Vieira, 2014, Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach, World J Biol. Psychiatry, 15, 84, 10.3109/15622975.2013.830775 · DOI
  73. Machado-Vieira, 2015, Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder, Eur. Neuropsychopharmacol., 25, 468, 10.1016/j.euroneuro.2015.02.002 · DOI
  74. Maes, 1998, Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity, Acta Psychiatr. Scand., 97, 302, 10.1111/j.1600-0447.1998.tb10004.x · DOI · Paper page
  75. Maj, 1991, Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats, J. Neural Transm. Gen. Sect., 85, 169, 10.1007/BF01244943 · DOI
  76. McClung, 2007, Circadian genes, rhythms and the biology of mood disorders, Pharmacol. Ther., 114, 222, 10.1016/j.pharmthera.2007.02.003 · DOI · Paper page
  77. Mealing, 1999, Differences in degree of trapping of low-affinity uncompetitive N-methyl-d-aspartic acid receptor antagonists with similar kinetics of block, J. Pharmacol. Exp. Ther., 288, 204, 10.1016/S0022-3565(24)37943-1 · DOI · Paper page
  78. Meloni, 1993, Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats, Pharmacol. Biochem. Behav., 46, 423, 10.1016/0091-3057(93)90374-3 · DOI
  79. Menniti, 2013, Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks, Curr. Top. Med. Chem., 13, 26, 10.2174/1568026611313010005 · DOI
  80. Messias, 2012, Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report, Prim Care Companion CNS Disord, 14, I01400
  81. Millan, 2005, Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade, Psychopharmacology (Berl.), 177, 448, 10.1007/s00213-004-1962-z · DOI · Paper page
  82. Mjellem, 1993, Reduction of NMDA-induced behaviour after acute and chronic administration of desipramine in mice, Neuropharmacology, 32, 591, 10.1016/0028-3908(93)90055-8 · DOI
  83. Montgomery, 2007, Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine, Int. Clin. Psychopharmacol., 22, 283, 10.1097/YIC.0b013e3280c56b13 · DOI
  84. Moryl, 1993, Potential antidepressive properties of amantadine, memantine and bifemelane, Pharmacol. Toxicol., 72, 394, 10.1111/j.1600-0773.1993.tb01351.x · DOI
  85. Moskal, 2014, GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists, Expert. Opin. Investig. Drugs, 23, 243, 10.1517/13543784.2014.852536 · DOI
  86. Musazzi, 2013, The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors, Biol. Psychiatry, 73, 1180, 10.1016/j.biopsych.2012.11.009 · DOI · Paper page
  87. Nagayama, 1996, Chronic administration of imipramine and lithium changes the phase-angle relationship between the activity and core body temperature circadian rhythms in rats, Chronobiol. Int., 13, 251, 10.3109/07420529609020905 · DOI
  88. Nathan, 1999, Melatonin sensitivity to dim white light in affective disorders, Neuropsychopharmacology, 21, 408, 10.1016/S0893-133X(99)00018-4 · DOI
  89. Nations, 2012, Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial, J. Psychopharmacol., 26, 1525, 10.1177/0269881112458728 · DOI
  90. Nduhirabandi, 2011, Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity, J. Pineal Res., 50, 171, 10.1111/j.1600-079X.2010.00826.x · DOI · Paper page
  91. Neubauer, 2008, A review of ramelteon in the treatment of sleep disorders, Neuropsychiatr. Dis. Treat., 4, 69, 10.2147/NDT.S483 · DOI
  92. Niciu, 2014, Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds, Annu. Rev. Pharmacol. Toxicol., 54, 119, 10.1146/annurev-pharmtox-011613-135950 · DOI · Paper page
  93. Norris, 2013, A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder, J. Affect Disord., 144, 141, 10.1016/j.jad.2012.06.023 · DOI
  94. Nowak, 1998, Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors, Eur. J. Pharmacol., 342, 367, 10.1016/S0014-2999(97)01589-6 · DOI
  95. Nowak, 1993, Adaptive changes in the N-methyl-d-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid, J. Pharmacol. Exp. Ther., 265, 1380, 10.1016/S0022-3565(25)38235-2 · DOI · Paper page
  96. Nurnberger, 2000, Melatonin suppression by light in euthymic bipolar and unipolar patients, Arch. Gen. Psychiatry, 57, 572, 10.1001/archpsyc.57.6.572 · DOI · Paper page
  97. Nurnberger, 1988, Supersensitivity to melatonin suppression by light in young people at high risk for affective disorder. A preliminary report, Neuropsychopharmacology, 1, 217, 10.1016/0893-133X(88)90020-6 · DOI
  98. O’Neill, 1999, A single pretreatment with MK-801 or cocaine enhances their locomotor stimulant effects in rats, Brain Res., 834, 103, 10.1016/S0006-8993(99)01580-2 · DOI
  99. O’Neill, 2004, AMPA receptor potentiators for the treatment of CNS disorders, Curr. Drug Targets CNS Neurol. Disord., 3, 181, 10.2174/1568007043337508 · DOI · Paper page
  100. O’Neill, 2007, AMPA receptor potentiators: application for depression and Parkinson's disease, Curr. Drug Targets, 8, 603, 10.2174/138945007780618517 · DOI
  101. Ohgi, 2015, Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders, Curr. Mol. Med., 15, 206, 10.2174/1566524015666150330143008 · DOI · Paper page
  102. Pacchierotti, 2001, Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry, Front. Neuroendocrinol., 22, 18, 10.1006/frne.2000.0202 · DOI · Paper page
  103. Papp, 2003, Effect of agomelatine in the chronic mild stress model of depression in the rat, Neuropsychopharmacology, 28, 694, 10.1038/sj.npp.1300091 · DOI · Paper page
  104. Paul, 1994, Adaptation of the N-methyl-d-aspartate receptor complex following chronic antidepressant treatments, J. Pharmacol. Exp. Ther., 269, 95, 10.1016/S0022-3565(25)38715-X · DOI · Paper page
  105. Paul, 1992, Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists, Psychopharmacology (Berl.), 106, 285, 10.1007/BF02801986 · DOI
  106. Petty, 1985, Intracortical glutamate injection produces helpless-like behavior in the rat, Pharmacol. Biochem. Behav., 22, 531, 10.1016/0091-3057(85)90270-9 · DOI
  107. Pilc, 2013, Glutamate-based antidepressants: preclinical psychopharmacology, Biol. Psychiatry, 73, 1125, 10.1016/j.biopsych.2013.01.021 · DOI
  108. Preskorn, 2008, An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist CP-101,606, in patients with treatment-refractory major depressive disorder, J. Clin. Psychopharmacol., 28, 631, 10.1097/JCP.0b013e31818a6cea · DOI · Paper page
  109. Przegalinski, 1997, Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist, Neuropharmacology, 36, 31, 10.1016/S0028-3908(96)00157-8 · DOI
  110. Quiroz, 2014, The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomized, double-blind, placebo controlled study, Neuropsychopharmacology, 39, S376
  111. Rantamaki, 2008, Targeting TrkB neurotrophin receptor to treat depression, Expert Opin Ther Targets, 12, 705, 10.1517/14728222.12.6.705 · DOI · Paper page
  112. Rawls, 1998, Muscarinic receptors regulate extracellular glutamate levels in the rat striatum: An in vivo microdialysis study, J. Pharmacol. Exp. Ther., 286, 91, 10.1016/S0022-3565(24)37561-5 · DOI
  113. Redman, 1998, Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal, J. Biol. Rhythms, 13, 39, 10.1177/074873098128999907 · DOI
  114. Reiter, 2009, Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin, Crit. Rev. Biochem. Mol. Biol., 44, 175, 10.1080/10409230903044914 · DOI · Paper page
  115. Reynolds, 1988, [3H]MK801 binding to the N-methyl-d-aspartate receptor reveals drug interactions with the zinc and magnesium binding sites, J. Pharmacol. Exp. Ther., 247, 1025, 10.1016/S0022-3565(25)13253-9 · doi:10.1016/s0022-3565(25)13253-9
  116. Robson, 2012, Evaluation of sigma (sigma) receptors in the antidepressant-like effects of ketamine in vitro and in vivo, Eur. Neuropsychopharmacol., 22, 308, 10.1016/j.euroneuro.2011.08.002 · DOI
  117. Romo-Nava, 2014, Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial, Bipolar Disord., 16, 410, 10.1111/bdi.12196 · DOI
  118. Salvatore, 2008, Circadian activity rhythm abnormalities in ill and recovered bipolar I disorder patients, Bipolar Disord., 10, 256, 10.1111/j.1399-5618.2007.00505.x · DOI · Paper page
  119. Sanacora, 2012, Towards a glutamate hypothesis of depression. An emerging fronteir of neuropsychopharmacology for mood disorders, Neuropharmacology, 62, 63, 10.1016/j.neuropharm.2011.07.036 · DOI · Paper page
  120. Saricicek, 2011, Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial, J. Clin. Psychiatry, 72, 744, 10.4088/JCP.09m05659gre · DOI
  121. Scarr, 2003, Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder, Bipolar Disord., 5, 257, 10.1034/j.1399-5618.2003.00024.x · DOI
  122. Shah, 2014, Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine, Clin. Psychopharmacol. Neurosci., 12, 83, 10.9758/cpn.2014.12.2.83 · DOI
  123. Sills, 1989, Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and l-glutamate, Mol. Pharmacol., 36, 160, 10.1016/S0026-895X(25)00612-1 · DOI
  124. Singh, 2014, What is hydroxynorketamine and what can it bring to neurotherapeutics?, Expert. Rev. Neurother., 14, 1239, 10.1586/14737175.2014.971760 · DOI
  125. Skolnick, 1999, Antidepressants for the new millennium, Eur. J. Pharmacol., 375, 31, 10.1016/S0014-2999(99)00330-1 · DOI · Paper page
  126. Skolnick, 2002, Modulation of glutamate receptors: strategies for the development of novel antidepressants, Amino Acids, 23, 153, 10.1007/s00726-001-0121-7 · DOI
  127. Skolnick, 1996, Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression, Pharmacopsychiatry, 29, 23, 10.1055/s-2007-979537 · DOI · Paper page
  128. Srinivasan, 2006, Melatonin in mood disorders, World J Biol. Psychiatry, 7, 138, 10.1080/15622970600571822 · DOI · Paper page
  129. Thomson, 2005, Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor, Mol. Psychiatry, 10, 470, 10.1038/sj.mp.4001593 · DOI
  130. Tizabi, 2012, Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar–Kyoto rats, Neuroscience, 213, 72, 10.1016/j.neuroscience.2012.03.052 · DOI · Paper page
  131. Van Oekelen, 2003, 5-HT2A and 5-HT2C receptors and their atypical regulation properties, Life Sci., 72, 2429, 10.1016/S0024-3205(03)00141-3 · DOI · Paper page
  132. Vetulani, 1984, Complex action of antidepressant treatment on central adrenergic system: possible relevance to clinical effects, Pharmacopsychiatry, 17, 16, 10.1055/s-2007-1017401 · doi:10.1055/s-2007-1017401
  133. Voleti, 2013, Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses, Biol. Psychiatry, 74, 742, 10.1016/j.biopsych.2013.04.025 · DOI · Paper page
  134. Whalley, 1991, Melatonin response to bright light in recovered, drug-free, bipolar patients, Psychiatry Res., 38, 13, 10.1016/0165-1781(91)90048-T · DOI
  135. Wong, 1996, Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at μ-opioid receptors, Eur. J. Pharmacol., 297, 27, 10.1016/0014-2999(95)00728-8 · DOI
  136. Wood, 2009, Replicable differences in preferred circadian phase between bipolar disorder patients and control individuals, Psychiatry Res., 166, 201, 10.1016/j.psychres.2008.03.003 · DOI · Paper page
  137. Wu, 1990, The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis, Am. J. Psychiatry, 147, 14, 10.1176/ajp.147.1.14 · DOI · Paper page
  138. Wyatt, 2006, Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent, Sleep, 29, 609, 10.1093/sleep/29.5.609 · DOI · Paper page
  139. Yanagihara, 2003, Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers, Biopharm. Drug Dispos., 24, 37, 10.1002/bdd.336 · DOI · Paper page
  140. Yilmaz, 2002, Prolonged effect of an anesthetic dose of ketamine on behavioral despair, Pharmacol. Biochem. Behav., 71, 341, 10.1016/S0091-3057(01)00693-1 · DOI · Paper page
  141. Yu, 2013, Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway, Psychopharmacology (Berl.), 225, 361, 10.1007/s00213-012-2823-9 · DOI
  142. Zarate, 2013, Human biomarkers of rapid antidepressant effects, Biol. Psychiatry, 73, 1142, 10.1016/j.biopsych.2012.11.031 · DOI
  143. Zarate, 2005, An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression, Biol. Psychiatry, 57, 430, 10.1016/j.biopsych.2004.11.023 · DOI · Paper page
  144. Zimmer, 2015, Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone, J. Cereb. Blood Flow Metab., 35, 1169, 10.1038/jcbfm.2015.35 · DOI
  145. Zobel, 2000, Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated, J. Psychiatr. Res., 34, 171, 10.1016/S0022-3956(00)00016-9 · DOI · Paper page
  146. Zunszain, 2013, Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties, Mol. Psychiatry, 18, 1236, 10.1038/mp.2013.87 · DOI

Cited by

See all 154

Metadata

Authors
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A.
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2017-05
Volume
152
Pages
21-37
ISSN
0301-0082 (ISSN-L)
OpenAlex
W2208668986
Cited by
154
References
79
FWCI
10.36
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
National Institute of Mental Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New targets for rapid antidepressant action. https://app.cochat.ai/papers/10.1016/j.pneurobio.2015.12.001
The paper
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017). New targets for rapid antidepressant action. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2015.12.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.